- Home
- NCMI vs KZR Comparison
NCMI vs KZR Comparison
Compare NCMI & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCMI | KZR |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.7M | 45.8M |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NCMI | KZR |
|---|---|---|
| Price | $3.91 | $6.33 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $6.88 | $6.00 |
| AVG Volume (30 Days) | ★ 414.2K | 35.9K |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | ★ 3.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $236,300,000.00 | N/A |
| Revenue This Year | $3.66 | N/A |
| Revenue Next Year | $12.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.81 | $3.53 |
| 52 Week High | $7.25 | $6.95 |
Technical Indicators
Market Signals| Indicator | NCMI | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 62.51 |
| Support Level | $3.98 | $6.16 |
| Resistance Level | $4.12 | $6.33 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 1.09 | 80.00 |
Price Performance
Historical ComparisonAbout NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.